These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 33472356)
1. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. Ross DM; Babon JJ; Tvorogov D; Thomas D Haematologica; 2021 May; 106(5):1244-1253. PubMed ID: 33472356 [TBL] [Abstract][Full Text] [Related]
2. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936 [TBL] [Abstract][Full Text] [Related]
3. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662 [TBL] [Abstract][Full Text] [Related]
4. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Tvorogov D; Thomas D; Liau NPD; Dottore M; Barry EF; Lathi M; Kan WL; Hercus TR; Stomski F; Hughes TP; Tergaonkar V; Parker MW; Ross DM; Majeti R; Babon JJ; Lopez AF Sci Adv; 2018 Nov; 4(11):eaat3834. PubMed ID: 30498775 [TBL] [Abstract][Full Text] [Related]
5. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Greenfield G; McPherson S; Mills K; McMullin MF J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Rai S; Grockowiak E; Hansen N; Luque Paz D; Stoll CB; Hao-Shen H; Mild-Schneider G; Dirnhofer S; Farady CJ; Méndez-Ferrer S; Skoda RC Nat Commun; 2022 Sep; 13(1):5346. PubMed ID: 36100613 [TBL] [Abstract][Full Text] [Related]
7. Management of myelofibrosis after ruxolitinib failure. Harrison CN; Schaap N; Mesa RA Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525 [TBL] [Abstract][Full Text] [Related]
8. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774 [TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the treatment of myelofibrosis]. Takenaka K Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516 [TBL] [Abstract][Full Text] [Related]
10. Management of myelofibrosis after ruxolitinib failure. Bose P; Verstovsek S Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan. Chen YY; Huang CE; Lee KD; Chen CC Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121 [TBL] [Abstract][Full Text] [Related]
12. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center. Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592 [TBL] [Abstract][Full Text] [Related]
13. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
14. How many JAK inhibitors in myelofibrosis? Ferreira BV; Harrison C Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729 [TBL] [Abstract][Full Text] [Related]
15. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. O'Sullivan JM; Harrison CN Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129 [TBL] [Abstract][Full Text] [Related]
16. [Clinical application of gene mutation information in myeloproliferative neoplasms]. Takenaka K Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152 [TBL] [Abstract][Full Text] [Related]
18. Management of myelofibrosis: JAK inhibition and beyond. Stahl M; Zeidan AM Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559 [TBL] [Abstract][Full Text] [Related]
19. Definition and management of ruxolitinib treatment failure in myelofibrosis. Pardanani A; Tefferi A Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025 [TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib: a new treatment option for myelofibrosis. Ganetsky A Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]